Sionna Therapeutics, Inc. Common Stock
SIONSionna Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies targeting cell signaling pathways involved in oncology and other diseases. Leveraging advanced scientific research, the company aims to create novel treatments that address unmet medical needs in cancer and related conditions.
Company News
OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatm...
Sionna Therapeutics initiated a Phase 2a clinical trial evaluating SION-719, a novel NBD1 stabilizer, as an addition to standard cystic fibrosis treatment Trikafta. The trial aims to assess safety, tolerability, and potential improvement in CFTR protein function, with topline data expected in mid-2026.
Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising $219.2 million. The company is developing novel medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.
